CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Neurocrine begins Phase I trial of NBIP-‘1968 triple agonist for obesity

Phase 1NBIP-'1968Positive
AI Analysis

Summary

Neurocrine Biosciences has initiated a Phase 1 clinical trial evaluating NBIP-'1968, a triple agonist, as a potential treatment for obesity.

Clinical Trial Data

Phase

Phase 1

Importance:5/10
Sentiment:
0.30
obesitytriple agonistPhase 1clinical trial
Related Companies

Read the original article

Published by Clinical Trials Arena on August 10, 2026 8:44 AM

Read Original